Overview

Ceritinib, also known as LDK378, is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. Compared with the first-generation ALK inhibitor crizotinib, it is substantially more potent against ALK and retains activity against several crizotinib-resistance ALK mutations, while also inhibiting IGF-1R, insulin receptor and ROS1. It is approved for ALK-positive non-small cell lung cancer that has progressed on or is intolerant of crizotinib. Because ALK inhibition is the central mechanism, combination and sequencing strategies are built around sustaining that blockade. This article reviews the rationale.

Why Combine a Second-Generation ALK Inhibitor

Single-agent ALK inhibition transforms ALK-positive NSCLC, yet resistance still emerges, often through new ALK mutations or bypass pathways. Combining a potent ALK inhibitor with chemotherapy, or exploring it alongside other targeted or immune-modulating approaches, aims to deepen initial control and delay the emergence of resistance. The biological logic is that overlapping mechanisms reduce the chance any single escape route dominates. Any such program must balance added efficacy against cumulative toxicity, which is why combination design is evidence-led rather than empirical.

Sequencing and Combination Contexts

After progression on one ALK inhibitor, the next agent is chosen by the resistance mechanism, where known. Ceritinib's retained activity against several crizotinib-resistance ALK mutations makes it a logical sequential step, and its central nervous system penetration is relevant for brain metastases. Re-testing at progression clarifies whether to continue within the ALK class or switch mechanism. For procurement, this means demand follows biomarker-confirmed, sequentially treated populations rather than first-line breadth.

Combination design also depends on the resistance map for each patient. When progression follows a known ALK mutation, staying within the ALK class with an agent that covers that mutation is often preferred, whereas bypass signaling may call for a different pathway approach. This is why longitudinal molecular testing, not just the initial diagnosis, guides modern ALK-positive care. For suppliers, the practical takeaway is that ceritinib demand follows sequentially treated, biomarker-confirmed populations, so dependable batch availability and clear documentation matter more than broad market presence. Supporting prescribers with accurate, up-to-date labeling helps keep therapy aligned to the evolving resistance picture.

FAQ

Q: What distinguishes ceritinib from first-generation ALK inhibitors? A: Ceritinib is far more potent against ALK and retains activity against several crizotinib-resistance ALK mutations, while also inhibiting IGF-1R, insulin receptor and ROS1.

Q: Why consider combining ceritinib with other agents? A: Combining with chemotherapy or other targeted approaches may deepen response and slow resistance, though added toxicity requires careful evidence-led design.

Q: Does ceritinib reach the brain? A: Yes. It penetrates the central nervous system, which is clinically relevant for patients with brain metastases from ALK-positive disease.